Aptose Biosciences Inc (APTO)

[Decatsmeow]

Buy Aptose Biosciences. Inc. (APTO) As Analysts Give Buy Rating With A Price Target Of $9 (X5.5 ROI)!

Analysts set a price target of $9 (%550 ROI)
Both Short Term and Long Term Plays Can Be Made
Cancer/Tumor Profiling Market is poised to reach $61.87 Billion Dollars by 2021

Aptose Biosciences. Inc. (APTO) is a biotechnical company that looks to find treatments for cancers such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. With their research, APTO has discovered a form of treatment known as (CG'806) which is undergoing testing currently. On June 8, 2017, the company was rated as neutral by Rodman & Renshaw, and more recently was rated by analysts as a buy with a price target of $9 (%550). This news follows after a long period of decline, and signals a trend reversal for the stock! There's even growth to be found here in the short term. Earlier this week, the stock managed to break above the major upward resistance line of $1.55. This signals a near term move to $2.34 which is a very profitable 51% increase. Technicals are indeed indicating that money is to be made here!

Fundamentals for Aptose Biosciences are showing continued interest in their research. Investors large and small are aiding to continue the noble work they are doing. APTO currently has a very manageable amount of debt, with most of the expenses being paid. Aptoses' balance statement shows that APTO has ~$11,958,000 in on-hand cash with a total of ~$12,676,000 in overall business assets. These numbers added with the increase of good news from the company regarding their treatments' lab results are signals that we might be nearing excellent company growth.

Read More Here